Bioasis Technologies Inc. is a Vancouver-based biopharmaceutical company engaged in the development and commercialization of technologies for the diagnosis and treatment of central nervous system (CNS) disorders. Valued at more than US$98B, the CNS market segment is the second-largest category in the pharmaceutical industry and is growing at approximately 8% per annum. The World Health Organization has declared that CNS disorders represent the major medical challenge of the 21st century.